ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharma giant Gilead Sciences is licensing a potential medicine from Nurix Therapeutics, a developer of targeted protein modulators. The molecule is the first development candidate from a protein degradation therapy development collaboration that the two companies announced in 2019. Nurix will get $20 million up front and may earn up to $425 million in milestone payments.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter